Fed Chair Powell calls inflation ‘too high’ and warns that ‘we are prepared to raise rates further’

Federal Reserve Chair Jerome Powell on Friday called for more vigilance in the fight against inflation, warning that additional interest rate increases could be yet to come.

While acknowledging that progress has been made and saying the Fed will be careful in where it goes from here, the central bank leader said inflation is still above where policymakers feel comfortable. He noted that the Fed will remain flexible as it contemplates further moves, but gave little indication that it’s ready to start easing anytime soon.

“Although inflation has moved down from its peak — a welcome development — it remains too high,” Powell said in prepared remarks for his keynote address at the Kansas City Fed’s annual retreat in Jackson Hole, Wyoming. “We are prepared to raise rates further if appropriate, and intend to hold policy at a restrictive level until we are confident that inflation is moving sustainably down toward our objective.”

The speech resembled remarks Powell made last year at Jackson Hole, during which he warned that “some pain” was likely as the Fed continues its efforts to pull runaway inflation back down to its 2% goal.

But inflation was running well ahead of its current pace back then. Regardless, Powell indicated it’s too soon to declare victory, even with data this summer running largely in the Fed’s favor. June and July both saw easing in the pace of price increases, with core inflation up 0.2% for each month, according to the Bureau of Labor Statistics.

“The lower monthly readings for core inflation in June and July were welcome, but two months of good data are only the beginning of what it will take to build confidence that inflation is moving down sustainably toward our goal,” he said.

Powell acknowledged that risks are two-sided, with dangers of doing both too much and too little.

Powell's concerns about growth and the labor market being too strong are new, says Point72's Maki

“Doing too little could allow above-target inflation to become entrenched and ultimately require monetary policy to wring more persistent inflation from the economy at a high cost to employment,” he said. “Doing too much could also do unnecessary harm to the economy.”

“As is often the case, we are navigating by the stars under cloudy skies,” he added.

Markets were volatile after the speech, but stocks powered higher later in the day and Treasury yields were mostly up. In 2022, stocks plunged following Powell’s Jackson Hole speech.

“Was he hawkish? Yes. But given the jump in yields lately, he wasn’t as hawkish as some had feared,” said Ryan Detrick, chief market strategist at the Carson Group. “Remember, last year he took out the bazooka and was way more hawkish than anyone expected, which saw heavy selling into October. This time he hit it more down the middle, with no major changes in future hikes a welcome sign.”

A need to ‘proceed carefully’

Powell’s remarks follow a series of 11 interest rate hikes that have pushed the Fed’s key interest rate to a target range of 5.25%-5.5%, the highest level in more than 22 years. In addition, the Fed has reduced its balance sheet to its lowest level in more than two years, a process which was seen about $960 billion worth of bonds roll off since June 2022.

Markets of late have been pricing in little chance of another hike at the September meeting of the Federal Open Market Committee, but are pointing to about a 50-50 chance of a final increase at the November session. Projections released in June showed that almost all FOMC officials saw another hike likely this year.

Powell provided no clear indication of which way he sees the decision going.

“Given how far we have come, at upcoming meetings we are in a position to proceed carefully as we assess the incoming data and the evolving outlook and risks,” he said.

However, he gave no sign that he’s even considering a rate cut.

“At upcoming meetings, we will assess our progress based on the totality of the data and the evolving outlook and risks,” Powell said. “Based on this assessment, we will proceed carefully as we decide whether to tighten further or, instead, to hold the policy rate constant and await further data.”

The chair added that economic growth may have to slow before the Fed can change course.

Gross domestic product has increased steadily since the rate hikes began, and the third quarter of 2023 is tracking at a 5.9% growth pace, according to the Atlanta Fed. Employment also has stayed strong, with the jobless rate hovering around lows last seen in the late 1960s.

“The basic thought that they’re close to done, they think they probably have a little bit more to do … that is the story they’ve been telling for a little while. And that was the heart of what he said today,” said Bill English, a former Fed official and now a Yale finance professor.

“I don’t think this is about sending a signal. I think this is really where they think they are,” he added. “The economy has slowed some but not enough yet to make them confident inflation is going to come down.”

Indeed, Powell noted the risk of strong economic growth in the face of widespread recession expectations and how that could make the Fed hold rates higher for longer.

“It was a balanced but not trend-changing speech, even if the Fed kept the ‘mission accomplished’ banner in the closet,” said Jack McIntyre, portfolio manager at Brandywine Global. “It leaves the Fed with needed optionality to either tighten more or keep rates on hold.”

Getting into details

While last year’s speech was unusually brief, this time around Powell provided a little more detail into the factors that will go into policymaking.

Specifically, he broke inflation into three key metrics and said the Fed is most focused on core inflation, which excludes volatile food and energy prices. He also reiterated that the Fed most closely follows the personal consumption expenditures price index, a Commerce Department measure, rather than the Labor Department’s consumer price index.

The three “broad components” of which he spoke entail goods, housing services such as rental costs and nonhousing services. He noted progress on all three, but said nonhousing is the most difficult to gauge as it is the least sensitive to interest rate adjustments. That category includes such things as health care, food services and transportation.

“Twelve-month inflation in this sector has moved sideways since liftoff. Inflation measured over the past three and six months has declined, however, which is encouraging,” Powell said. “Given the size of this sector, some further progress here will be essential to restoring price stability.”

No change to inflation goal

In addition to the broader policy outlook, Powell honed in some areas that are key both to market and political considerations.

Some legislators, particularly on the Democratic side, have suggested the Fed raise its 2% inflation target, a move that would give it more policy flexibility and might deter further rate hikes. But Powell rejected that idea, as he has done in the past.

“Two percent is and will remain our inflation target,” he said.

That portion of the speech brought some criticism from Harvard economist Jason Furman.

“Jay Powell said all the right things about near-term monetary policy, continuing to hope for the best while planning for the worst. He was appropriately cautious on inflation progress & asymmetric about the policy stance,” Furman, who was chair of the Council of Economic Advisers under former President Barack Obama, posted on X, the social media site formerly known as Twitter. “But wish he had not ruled out shifting the target.”

On another issue, Powell chose largely to stay away from the debate over what is the longer-run, or natural, rate of interest that is neither restrictive nor stimulative – the “r-star” rate of which he spoke at Jackson Hole in 2018.

“We see the current stance of policy as restrictive, putting downward pressure on economic activity, hiring, and inflation,” he said. “But we cannot identify with certainty the neutral rate of interest, and thus there is always uncertainty about the precise level of monetary policy restraint.”

Powell also noted that the previous tightening moves likely haven’t made their way through the system yet, providing further caution for the future of policy.

Source link

#Fed #Chair #Powell #calls #inflation #high #warns #prepared #raise #rates

Weight loss drugs boost sales at retail pharmacies, but they may not help profits much

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. 

George Frey | Reuters

Drugmakers aren’t the only ones feeling the impact of the weight loss industry gold rush. 

Retailers with pharmacy businesses, such as Walmart, Kroger and Rite Aid, said increased demand for prescription weight loss drugs helped boost sales for the second quarter. 

But analysts note that those blockbuster treatments are minimally profitable for retail pharmacies – and may even come with margin headwinds.

“More recently, you’re starting to hear retailers talk about these drugs. But I wouldn’t say they’re necessarily beneficiaries of the increased popularity,” Arun Sundaram, an analyst at CFRA Research, told CNBC. “They’re really not making much of a profit on the drugs. So it’s really just a traffic driver and not really a profit pool for retailers.” 

Buzzy drugs like Novo Nordisk‘s obesity injection Wegovy and diabetes treatment Ozempic have skyrocketed in popularity over the last year, with high-profile names like billionaire tech mogul Elon Musk among recent users.

Those treatments are known as GLP-1s, a class of drugs that mimic a hormone produced in the gut to suppress a person’s appetite. 

Other drugmakers, such as Eli Lilly and Pfizer, are developing their own GLP-1s in a bid to capitalize on a weight loss drug market that some analysts project could be worth $200 billion by 2030. An estimated 40% of U.S. adults are obese, making successful treatments a massive opportunity for drugmakers. 

But the boom in demand for GLP-1s is also being felt in other parts of the drug supply chain, including the pharmacies that dispense the prescription drugs to patients. 

Are weight loss drugs profitable? 

On an earnings call Thursday, Walmart CEO Doug McMillon said the company expects weight loss drugs to help drive sales for the rest of the year: “We still expect food, consumables, and health and wellness, primarily due to the popularity of some GLP-1 drugs, to grow as a percent total in the back half.” 

In June, likewise, Rite Aid CFO Matthew Schroeder said a jump in pharmacy revenue and the company’s decision to hike its full-year revenue guidance was “due to the increase in sales volume in Ozempic and other high-dollar GLP-1s.” Schroeder was referring to the hefty price tags of GLP-1s, which range from around $900 to $1,300 in the U.S. 

He said those drugs have high sales amounts per prescription, but emphasized that the increased volume of GLP-1s has a “minimal impact” on Rite Aid’s gross profit. 

Kroger CEO Rodney McMullen similarly said during an earnings call in June that GLP-1 drug “sales dollars are a lot bigger than the margin dollars.” 

“We would expect the GLP-1 type drugs to continue but remember, the impact on profitability is pretty narrow,” he said.

That’s because GLP-1s like Wegovy and Ozempic are branded drugs with “very, very low gross margins,” according to CFRA Research’s Sundaram. 

He said retail pharmacies generate high sales for each GLP-1 prescription they dispense but rake in low profits, which is having a slight negative impact on the overall gross margins of retailers like Walmart and Kroger. 

UBS analyst Michael Lasser similarly highlighted in a recent note that gross margins for Walmart’s U.S. business “would have looked even better had it not been for the contribution of the GLP-1 drugs since these carry very low profit rates.”

A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. 

Jim Vondruska | Reuters

Gross margins for branded medications are 3.5% on average for pharmacies, according to a 2017 study from USC’s Schaeffer Center for Health Policy and Economics. That suggests it may take years before a branded drug significantly contributes to a pharmacy’s bottom line.

In contrast, gross margins for generic drugs – the cheaper equivalents of branded medications – are 42.7% on average for pharmacies. 

There are several reasons for the lower margins of branded drugs. For one, branded drugs don’t directly compete with other medications because they have patent protections. That gives drug manufacturers more power when they negotiate drug discounts with wholesalers, which purchase medications and distribute them to pharmacies. 

As a result, there is “little room for wholesalers and pharmacies to capture large margins due to their relative lack of negotiating power,” according to the Association for Accessible Medicines, a trade association representing the manufacturers and distributors of generic prescription drugs. 

What other impacts do retailers face?

But there are also other impacts of GLP-1s to consider beyond a retailer’s pharmacy business.

For companies like Walmart and Kroger, GLP-1 drugs may be indirectly impacting other business categories in a positive way.

That makes some analysts less worried about margin headwinds in pharmacy: “The gross margin headwind is less of a risk overall for Walmart because any footstep in the door often ends up with multiple items in a basket,” KeyBanc analyst Bradley Thomas told CNBC. 

“Walmart is generally not a quick store that you just pop in on the way home,” he said. “They’re going to make multiple purchases, and I think we’re seeing a lot of discretionary categories actually see a lift from some of this incremental traffic they’ve been getting lately.” 

Thomas added that GLP-1 drugs only fall under one part of Walmart’s business: “If you’re listing off the most important things that are driving Walmart’s strong sales performance right now, it’s probably not making the top 10,” he said. 

It’s a slightly different situation for Rite-Aid and similar companies like CVS Health and Walgreens.

Those companies have retail pharmacies but also other business segments that are directly affected in different ways by the boom in GLP-1 drugs.

For example, CVS also operates a health insurer and pharmacy benefit manager, or PBM, which maintains formularies and negotiates drug discounts with manufacturers on behalf of insurers and large employers.

The increased demand for GLP-1 drugs is likely more of a headwind for health insurers since they have to cover the costly drugs for beneficiaries, but CVS says “the risk is manageable” in that business division.

Meanwhile, PBMs may benefit more from the increase in GLP-1 use since they negotiate significant discounts on drugs and drive competition between manufacturers – but they often don’t pass along all of the savings to insurers.

“Each of the businesses kind of has GLP-1 in them and they are impacting them in a variety of different ways,” CVS CEO Karen Lynch said during an earnings call last month.

Correction: The Association for Accessible Medicines is a trade association representing the manufacturers and distributors of generic prescription drugs. An earlier version misstated its name.

Source link

#Weight #loss #drugs #boost #sales #retail #pharmacies #profits

FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall

A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022.

Johanna Geron | Reuters

The U.S. Food and Drug Administration‘s independent panel of advisors on Thursday recommended that updated Covid shots for the fall and winter target one of the XBB variants, which are now the dominant strains of the virus nationwide. 

The committee unanimously voted that the new jabs should be monovalent — meaning they are designed to protect against one variant of Covid — and target a member of the XBB family.

Those strains of Covid are descendants of the omicron variant, which caused cases to surge to record levels early last year. They are some of the most immune-evasive strains to date.

Advisors also generally agreed that the new shots should specifically target a variant called XBB.1.5. The panel only discussed that specific strain selection and did not vote on the matter.

XBB.1.5 accounted for nearly 40% of all Covid cases in the U.S. as of early June, according to data from the Centers for Disease Control and Prevention. That proportion is slowly declining, and cases of the related XBB.1.16 and XBB.2.3 variants are on the rise. 

Advisors noted that XBB.1.5 appears most ideal for the fall since vaccine manufacturers Pfizer, Moderna and Novavax have already started to develop jabs targeting the strain.

“The 1.5 looks good. It seems like it’s the most feasible to get across the finish line early without resulting in delays and availability,” said Dr. Melinda Wharton, a senior official at the National Center for Immunization and Respiratory Diseases. “The vaccine we can use is the vaccine that we can get. And so it feels like this would be a good choice.”

The FDA typically follows the advice of its advisory committees, but is not required to do so. It’s unclear when the agency will make a final decision on strain selection.

There is also uncertainty about which age groups the FDA and CDC will advise to receive the updated shots this fall.

But the panel’s recommendation is already a win for Pfizer, Moderna and Novavax — all of which have been conducting early trials on their respective XBB.1.5 shots ahead of the meeting.

“Novavax expects to be ready for the commercial delivery of a protein-based monovalent XBB COVID vaccine this fall in line with today’s [advisory committee] recommendation,” said John Jacobs, the company’s president and CEO.

The U.S. is expected to shift vaccine distribution to the private sector this fall. That means the vaccine makers will start selling their new Covid products directly to health-care providers and vie for commercial market share. 

The panel’s recommendation coincides with a broader shift in how the pandemic impacts the country and the world at large. 

Covid cases and deaths have dropped to new lows, governments have rolled back stringent health mandates like masking and social distancing and many people believe the pandemic is over altogether.  

But Dr. Peter Marks, head of the FDA’s vaccine division, said the agency is concerned that the U.S. will have another Covid wave “during a time when the virus has further evolved, immunity of the population has waned further and we move indoors for wintertime.”

Updated Covid vaccines that are periodically updated to target a high circulating variant will restore protective immunity against the virus, said Dr. David Kaslow, a senior official in the FDA’s vaccine division. 

It’s a similar approach to how the strains are selected for the annual flu shot. Researchers assess strains of the virus in circulation and estimate which will be the most prevalent during the upcoming fall and winter.

But it’s unclear how many Americans will roll up their sleeves to take the updated shots later this year. 

Only about 17% of the U.S. population — around 56 million people —have received Pfizer and Moderna’s boosters since they were approved in September, according to the CDC.

More than 40% of adults 65 and older have been boosted with those shots, while the rate among younger adults and children ranges between 18% and 20%.

Those boosters were bivalent, meaning they targeted the original strain of Covid and the omicron subvariants BA.4 and BA.5. 

Pfizer, Moderna and Novavax shot data

During the meeting, Pfizer, Moderna and Novavax presented preliminary data on updated versions of their shots designed to target XBB variants. 

Moderna has been evaluating shots targeting XBB.1.5 and XBB.1.16 — another transmissible omicron descendant, according to Rituparna Das, the company’s vice president of Covid vaccines. 

Preclinical trial data on mice suggests that a monovalent vaccine targeting XBB.1.5 produces a more robust immune response against the currently circulating XBB variants than the authorized bivalent shot targeting BA.4 and BA.5, according to Das. 

She added that clinical trial data on more than 100 people similarly demonstrates that the monovalent XBB.1.5 vaccine produces protective antibodies against all XBB variants. All trial participants had previously received four Covid vaccine doses.

Das said that comprehensive protection against XBB strains is likely due to the fewer unique mutations between the variants, which means their composition is similar.

There are only three unique mutations between the variants XBB.1.5 and XBB.1.16, according to Darin Edwards, Moderna’s Covid vaccine program leader. By comparison, there are 28 mutations between omicron BA.4 and BA.5.

That means the immune response an updated shot produces against XBB variants will likely be similar, regardless of which specific variant it targets, Edwards said.

Pfizer also presented early trial data indicating that a monovalent vaccine targeting an XBB variant offers improved immune responses against the XBB family. 

The company provided specific timelines for delivering an updated vaccine, depending on the strain the FDA selects. 

Pfizer will be able to deliver a monovalent shot targeting XBB.1.5 by July and a jab targeting XBB.1.16 by August, according to Kena Swanson, the company’s senior principal scientist.

Pfizer won’t be able to distribute a new shot until October if the FDA chooses a completely different strain, Swanson said.

Novavax did not provide a specific timeline for delivering a shot targeting XBB.1.5, but noted that an XBB.1.16 shot would take eight weeks longer.

Novavax unveiled preclinical trial data indicating that monovalent vaccines targeting XBB.1.5 and XBB.1.16 induce higher immune responses to XBB subvariants than bivalent vaccines do. 

Data also demonstrates that an XBB.1.5 shot produces antibodies that block XBB.2.3 from binding to and infecting human cells, according to Dr. Filip Dubovsky, Novavax’s chief medical officer.

Dubovsky said the trial results support the use of a monovalent XBB.1.5 shot in the fall.

Novavax’s jab uses protein-based technology, a decades-old method for fighting viruses used in routine vaccinations against hepatitis B and shingles.

The vaccine works differently than Pfizer’s and Moderna’s messenger RNA vaccines but achieves the same outcome: teaching your body how to fight Covid.

Source link

#FDA #advisors #recommend #Covid #vaccines #target #omicron #XBB #variant #fall

Mano Ganesan moots Tamil caucus in Sri Lankan Parliament

In a bid to ensure Sri Lanka’s main political parties do not “take numerical minorities for granted” anymore, Opposition MP Mano Ganesan has recently mooted setting up a “Tamil caucus” in Parliament.

The “caucus”, he said, would allow Tamil legislators to express the “collective desire” of the island’s Tamil speaking peoples. Although Sri Lanka’s Tamils in the north and east, the Malaiyaha Tamils living across Central, Uva, Southern and Western Provinces, and the Tamil-speaking Muslims, may have different aspirations and political aims, their shared desire to live “within an undivided Sri Lanka, sharing wealth and power as combined stake holders of national sovereignty” must be collectively articulated, the leader of the Tamil Progressive Alliance (TPA) said.

“It [the caucus] will help us commence a collective dialogue with all the national political parties, and beyond politicians, reach out to the Sinhala community leaders and organisations; as well as the international community and development partners, and urge them to use their good offices to ensure Sri Lanka stands by its international commitments,” Mr. Ganesan told The Hindu at his Colombo residence. So far, some parties have responded positively, he said.

Also read | Sri Lanka MP Mano Ganesan seeks assistance from T.N. CM for Indian-origin Tamils in Sri Lanka

Currently part of the main Opposition alliance led by Samagi Jana Balawegaya (SJB or United People’s Force), the TPA, representing Malaiyaha Tamils, was among the few political groups to retain all of its six parliamentary seats in the last general election. Mr. Ganesan’s recent outreach comes amid speculation over national elections next year. Sri Lanka’s twice-postponed — owing to “lack of funds” — local government elections may not be held anytime soon, despite Sri Lanka’s Supreme Court restraining authorities from withholding funds, but all signs point to a presidential poll early next year, according to the legislator.

Presidential poll

“I met President Ranil Wickremesinghe one-on-one recently. He told me that he would run [for President],” said Mr. Ganesan, who was a Cabinet minister in the former Sirisena-Wickremesinghe administration.

Six-time Prime Minister Mr. Wickremesinghe was elected President through an urgent parliamentary vote in in July 2022, after Gotabaya Rajapaksa was unceremoniously ousted by a people’s uprising at the height of Sri Lanka’s crisis. The country’s constitution bars a President elected by Parliament when the office falls vacant as it did last year, from calling for early elections. Such a move would require a constitutional amendment, and possibly a referendum.

Mr. Ganesan said his efforts in uniting Mr. Wickremesinghe’s United National Party, diminished to a single parliamentary seat in the last election, and the breakaway SJB proved futile. Predicting a three-cornered contest in the next presidential election, Mr. Ganesan said Leader of Opposition Sajith Premadasa, and the Leader of the leftist Janatha Vimukthi Peramuna (JVP), were the other likely contenders to the country’s top office.

“It appears that Mr. Wickremesinghe hopes to be the common candidate in an entity that brings young members of both, the SLPP [Rajapaksas’ ruling Sri Lanka Podujana Peramuna or People’s Front], and the SJB, along with the minority parties together,” the MP said, adding that the TPA would engage with all parties and decide closer to the elections. “We will fit in with any government,” he said, if it is receptive to the Malaiyaha Tamils’ demands.

In Mr. Ganesan’s view, it is “too early” to comment on the President’s efforts towards economic recovery, but the increase in tourist arrivals and worker remittances are “positive” signs, although much remains to be done. “The Sri Lankan economy crashed due to three main reasons — corruption, mismanagement & wastage. I have not seen any serious efforts from the government other than the notice of the anti-corruption bill. Pity, President Wickremesinghe is living with the wolves.”

Making a case for closer trade ties with Sri Lanka’s international partners, the TPA Leader said greater access to the Indian market, with preferential trade terms, will help small and medium enterprises in Sri Lanka. “India is booming as the world’s 5th largest economy. Look at booming Tamil Nadu, the closest Indian state [to us]…We must grab this opportunity and grow with India.”

Recalling Prime Minister Narendra Modi’s first meeting with the TPA delegation in Colombo years ago, Mr. Ganesan said: “He [Mr. Modi] told us ‘Tamils should be united’, but immediately qualified his statement saying that ‘Tamil unity should strengthen Sri Lankan Unity’. Whether it is the BJP or the Congress, Indian national policy is unity in diversity. They preach to us what they practice at home,” he said, adding that India was Sri Lanka’s “greatest security shield” against any internal or external challenges. “Sri Lanka should understand this basis and come over semi-hostile phobia.”

Meanwhile, Sri Lanka must stop playing India and China against each other, he contended. “Mainstream Sinhalese politicians thought they were being clever in using India-China rivalries. But this foolishness has brought this country to this level,” he said, adding: “India is our greatest security shield against any internal or external challenges. Sri Lanka should understand this.”

200th year

Sri Lanka is marking the 200th year since the British brought down indentured labourers from south India to work in the island’s plantations. The British government has a “moral responsibility” towards the community who developed the profitable tea export industry, the island’s motor and railroad network, and the Colombo port in then Ceylon, he stressed. “I have started a dialogue with the British establishment on this recently.”

The responsibility of Indian state “is equal or even more”. “Our people were subjected to arbitrary and involuntary repatriation to India, notably by the Sirimavo-Shastri pact (1964)…We were not consulted, but treated like cattle,” he said. “Indians thought keeping Colombo happy served its national interests. This greatly diminished the political status and socio-economic wellbeing of our community. If not for this repatriation pact, the current strength of our MPs in Parliament of Sri Lanka, which is nine today, would have reached not less than 25.”

The Indian government and policy makers have been briefed “many times,” Mr. Ganesan said, expressing disappointment over the execution on ongoing projects. “India is helping build [14,000] houses for the families living in the plantations, but it is going on at a frighteningly sluggish pace. At this rate, it may take another 50 years to complete the project. Generous socio-cultural- economic development projects of India in Sri Lanka seldom reach our community,” he said. “Even in Tamil Nadu, most think that Sri Lanka’s Tamils live just in the north and east. Their awareness of the plight of Malaiyaha Tamils is very low,” he said.

Source link

#Mano #Ganesan #moots #Tamil #caucus #Sri #Lankan #Parliament

morning digest march 14 2023

A file photo of Afghan students protesting in Bengaluru against the Taliban takeover of Afghanistan.
| Photo Credit: PTI

Chaos over Rahul Gandhi’s comments in London as Parliament resumes after break

Children of lesbian, gay parents do not necessarily become lesbians, gays: SC informs government

Growing up with lesbian or gay parents will not necessarily make a child lesbian or gay, a puzzled Supreme Court on March 13, 2023 confronted the government’s concern about the “psychological” impact same-sex marriages may have on children.

Chief Justice D.Y. Chandrachud referred petitions seeking legal recognition of same-sex marriages to a Constitution Bench, but took the time on Monday to soothe the government’s anxiety about how such a move would affect Indian “social ethos”.

Chaos over Rahul Gandhi’s comments in London as Parliament resumes after break

As the second leg of the Budget Session commenced on Monday, March 13, after a month-long recess, none of the two Houses could transact significant business before being adjourned for the day amid ruckus by both members in the Treasury and Opposition Benches over Congress MP Rahul Gandhi’s recent remarks on India’s democracy in London. 

Despite lack of recognition, Taliban claims Indian Mission invited officials for online training programmes

Reports of an alleged decision by the Ministry of External Affairs (MEA) to hold courses for Afghans, including Taliban officials, in Kabul have set off strong reactions among Afghan students who have been denied visas by New Delhi for nearly two years. They termed the decision “contrary to India’s policy” and “disappointing”.

EPF Board meet pushed to March 27-28

The government on Monday announced the deferral of a meeting of the Employees’ Provident Fund Organisation (EPFO) board, where it is expected to finalise the EPF rate to be paid on crores of formal sector workers’ retirement savings in its custody for 2022-23.

Get additional funds to implement SC order on higher provident fund pension: Panel to Centre

The Labour Standing Committee of Parliament, headed by senior Biju Janata Dal leader Bhartruhari Mahtab, has pulled up the Union Labour Ministry for underutilisation of the allocations meant for the Ministry’s schemes. The panel asked the Ministry to assess and work out the likely financial implication for implementing the Supreme Court judgment on higher provident fund pension and approach the Ministry of Finance for additional funds to enable timely payment of amounts that may become due.

EC tells Allahabad HC it does not have power to ban caste rallies by parties in non-election period

The Election Commission of India (EC) does not have the jurisdiction to restrict caste-based political rallies held by political parties during non-election period, and nor does it have the power to ban such parties from contesting subsequent elections, the election watchdog has submitted before a Bench of the Allahabad High Court, responding to a writ petition that sought a ban on all such political rallies.

Supreme Court asks CBI not to continue probe into charges that BJP conspired to poach BRS legislators

The Supreme Court on Monday asked the Central Bureau of Investigation (CBI) to hold its investigation into allegations that the BJP conspired to poach Telangana’s Bharat Rashtra Samiti (BRS) legislators.

“The investigation is not to be continued while the matter is sub judice or it will become infructuous. That is the thumb rule,” a Bench led by Justice Sanjiv Khanna orally said.

India remains biggest arms importer between 2018-22 despite drop in overall imports

India remained the world’s largest arms importer for the five-year period between 2018-22 even though its arms imports dropped by 11% between 2013–17 and 2018–22, according to the Swedish Think Tank Stockholm International Peace Research Institute (SIPRI). Russia was the largest supplier of arms to India in both 2013–17 and 2018–22, but its share of total Indian arms imports fell from 64% to 45% while France emerged as the second largest supplier between 2018-22.

Activists, MPs flag RTI amendment in data protection bill

Activists and Opposition Members of Parliament on March 13 expressed concern that a proposed amendment to the Right to Information Act, 2005, could close off avenues to citizens to uncover corruption. Section 8(1)(j) of the RTI Act allows public authorities to refuse access to information if it intrudes on the privacy of an individual, but permits disclosure of information if there is an overriding public interest. 

Russia an ‘acute’ threat, China an ‘epoch defining’ challenge: U.K. Government

The U.K. government called Russia the “most acute threat” to Britain’s security and termed China an “epoch-defining” challenge, as it released a ‘refresh’ of its foreign and security policy, the Integrated Review 2023 (IR2023), two years after the first version (IR2021) was released.

149 air travellers put on ‘no-fly list’ in the past three years, says govt.

As many as 149 air travellers have been banned by airlines and put on the “no-fly list” in the past three years for unruly conduct, the government told Parliament on Monday.

Of these, smoking inside aircraft lavatory, drunken behaviour and a brawl with cabin crew and fellow passengers are most common.

ATK Mohun Bagan oust Hyderabad FC, set up ISL final with Bengaluru FC

ATK Mohun Bagan edged out defending champions Hyderabad FC 4-3 in a nail-biting penalty shootout in the Indian Super League semifinal in Kolkata on Monday.

Locked 0-0 in the first leg, the reverse fixture also saw a goalless stalemate till 120 minutes of play, including regulation and extra time.

Imran Khan leads thousands at election rally in Lahore as Islamabad police arrive to arrest him

Pakistan’s ousted premier Imran Khan on March 13, 2023 led a march of thousands of his supporters as Islamabad police arrived here to arrest him after two non-bailable arrest warrants were issued against him, a day after he called off his party’s election rally following a ban on public gatherings in Punjab’s provincial capital.

Source link

#morning #digest #march